Raras
Buscar doenças, sintomas, genes...
Pseudohiperaldosteronismo
ORPHA:444916CID-10 · N25.8DOENÇA RARA

Distúrbio hereditário ou adquirido do metabolismo eletrolítico, caracterizado pela incapacidade dos túbulos renais de responder à aldosterona. Manifesta-se por acidose metabólica hipercalêmica, perda de sal urinário, secreção normal ou aumentada de aldosterona e taxa de filtração glomerular normal.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

Distúrbio hereditário ou adquirido do metabolismo eletrolítico, caracterizado pela incapacidade dos túbulos renais de responder à aldosterona. Manifesta-se por acidose metabólica hipercalêmica, perda de sal urinário, secreção normal ou aumentada de aldosterona e taxa de filtração glomerular normal.

Pesquisas ativas
3 ensaios
12 total registrados no ClinicalTrials.gov
Publicações científicas
859 artigos
Último publicado: 2026 Mar 23
Medicamentos
1 registrados
ENALAPRIL

Tem tratamento?

1 medicamento registrado
Ver detalhes, fases e interações →
ENALAPRIL
🏥
SUS: Sem cobertura SUSScore: 0%
CID-10: N25.8
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

📏
Crescimento
6 sintomas
🫃
Digestivo
3 sintomas
🦴
Ossos e articulações
3 sintomas
🫁
Pulmão
3 sintomas
🫘
Rins
2 sintomas
🧬
Pele e cabelo
1 sintomas

+ 25 sintomas em outras categorias

Características mais comuns

Vômitos
Hipercalemia
Déficit de crescimento
Hiponatremia
Hipotensão
Hiperaldosteronismo
46sintomas
Sem dados (46)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 46 características clínicas mais associadas, ordenadas por frequência.

VômitosVomiting
HipercalemiaHyperkalemia
Déficit de crescimentoFailure to thrive
HiponatremiaHyponatremia
HipotensãoHypotension

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico859PubMed
Últimos 10 anos200publicações
Pico202241 papers
Linha do tempo
2026Hoje · 2026🧪 1992Primeiro ensaio clínico📈 2022Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

8 genes identificados com associação a esta condição.

CUL3Cullin-3Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Core component of multiple cullin-RING-based BCR (BTB-CUL3-RBX1) E3 ubiquitin-protein ligase complexes which mediate the ubiquitination and subsequent proteasomal degradation of target proteins. BCR complexes and ARIH1 collaborate in tandem to mediate ubiquitination of target proteins (PubMed:27565346). As a scaffold protein may contribute to catalysis through positioning of the substrate and the ubiquitin-conjugating enzyme. The E3 ubiquitin-protein ligase activity of the complex is dependent o

LOCALIZAÇÃO

NucleusGolgi apparatusCell projection, cilium, flagellumCytoplasm, cytoskeleton, spindleCytoplasmCytoplasm, cytoskeleton, microtubule organizing center, centrosomeCytoplasm, cytoskeleton, spindle pole

VIAS BIOLÓGICAS (8)
Antigen processing: Ubiquitination & Proteasome degradationNeddylationRegulation of RAS by GAPsDegradation of DVLSPOP-mediated proteasomal degradation of PD-L1(CD274)
MECANISMO DE DOENÇA

Pseudohypoaldosteronism 2E

An autosomal dominant disorder characterized by severe hypertension, hyperkalemia, hyperchloremia, hyperchloremic metabolic acidosis, and correction of physiologic abnormalities by thiazide diuretics.

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
100.6 TPM
Linfócitos
31.7 TPM
Músculo esquelético
29.4 TPM
Fibroblastos
25.3 TPM
Esôfago - Mucosa
23.8 TPM
OUTRAS DOENÇAS (3)
neurodevelopmental disorder with or without autism or seizurespseudohypoaldosteronism type 2Ecomplex neurodevelopmental disorder
HGNC:2553UniProt:Q13618
WNK1Serine/threonine-protein kinase WNK1Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Serine/threonine-protein kinase component of the WNK1-SPAK/OSR1 kinase cascade, which acts as a key regulator of blood pressure and regulatory volume increase by promoting ion influx (PubMed:15883153, PubMed:17190791, PubMed:31656913, PubMed:34289367, PubMed:36318922). WNK1 mediates regulatory volume increase in response to hyperosmotic stress by acting as a molecular crowding sensor, which senses cell shrinkage and mediates formation of a membraneless compartment by undergoing liquid-liquid pha

LOCALIZAÇÃO

CytoplasmNucleusCytoplasm, cytoskeleton, spindle

VIAS BIOLÓGICAS (1)
Stimuli-sensing channels
MECANISMO DE DOENÇA

Pseudohypoaldosteronism 2C

An autosomal dominant disorder characterized by severe hypertension, hyperkalemia, hyperchloremia, mild hyperchloremic metabolic acidosis in some cases, and correction of physiologic abnormalities by thiazide diuretics.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Brain Spinal cord cervical c-1
133.1 TPM
Linfócitos
83.2 TPM
Skin Sun Exposed Lower leg
76.8 TPM
Substância negra
68.2 TPM
Vagina
65.2 TPM
OUTRAS DOENÇAS (3)
neuropathy, hereditary sensory and autonomic, type 2Apseudohypoaldosteronism type 2Chereditary sensory and autonomic neuropathy type 2
HGNC:14540UniProt:Q9H4A3
WNK4Serine/threonine-protein kinase WNK4Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Serine/threonine-protein kinase component of the WNK4-SPAK/OSR1 kinase cascade, which acts as a key regulator of ion transport in the distal nephron and blood pressure (By similarity). The WNK4-SPAK/OSR1 kinase cascade is composed of WNK4, which mediates phosphorylation and activation of downstream kinases OXSR1/OSR1 and STK39/SPAK (PubMed:16832045). Following activation, OXSR1/OSR1 and STK39/SPAK catalyze phosphorylation of ion cotransporters, such as SLC12A1/NKCC2, SLC12A2/NKCC1, SLC12A3/NCC,

LOCALIZAÇÃO

Cell junction, tight junction

VIAS BIOLÓGICAS (1)
Stimuli-sensing channels
MECANISMO DE DOENÇA

Pseudohypoaldosteronism 2B

An autosomal dominant disorder characterized by hypertension, hyperkalemia, hyperchloremia, mild hyperchloremic metabolic acidosis, and correction of physiologic abnormalities by thiazide diuretics.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Tecido-específico)
Rim - Medula
52.5 TPM
Próstata
20.9 TPM
Rim - Córtex
16.2 TPM
Cólon transverso
14.7 TPM
Esôfago - Mucosa
12.5 TPM
OUTRAS DOENÇAS (1)
pseudohypoaldosteronism type 2B
HGNC:14544UniProt:Q96J92
NR3C2Mineralocorticoid receptorDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Receptor for both mineralocorticoids (MC) such as aldosterone and glucocorticoids (GC) such as corticosterone or cortisol. Binds to mineralocorticoid response elements (MRE) and transactivates target genes. The effect of MC is to increase ion and water transport and thus raise extracellular fluid volume and blood pressure and lower potassium levels

LOCALIZAÇÃO

CytoplasmNucleusEndoplasmic reticulum membrane

VIAS BIOLÓGICAS (2)
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligandSUMOylation of intracellular receptors
MECANISMO DE DOENÇA

Pseudohypoaldosteronism 1, autosomal dominant

A salt wasting disease resulting from target organ unresponsiveness to mineralocorticoids. PHA1A is a mild form characterized by target organ defects confined to kidney. Patients may present with neonatal renal salt wasting with hyperkalaemic acidosis despite high aldosterone levels. These patients improve with age and usually become asymptomatic without treatment.

EXPRESSÃO TECIDUAL(Ubíquo)
Tireoide
19.3 TPM
Ovário
13.1 TPM
Cólon transverso
12.7 TPM
Cérebro - Hemisfério cerebelar
12.0 TPM
Cervix Ectocervix
11.8 TPM
OUTRAS DOENÇAS (2)
autosomal dominant pseudohypoaldosteronism type 1pseudohyperaldosteronism type 2
HGNC:7979UniProt:P08235
SCNN1AEpithelial sodium channel subunit alphaDisease-causing germline mutation(s) inTolerante
FUNÇÃO

This is one of the three pore-forming subunits of the heterotrimeric epithelial sodium channel (ENaC), a critical regulator of sodium balance and fluid homeostasis (PubMed:30251954, PubMed:32729833, PubMed:8023962, PubMed:8278374, PubMed:9792722). ENaC operates in epithelial tissues, where it mediates the electrodiffusion of sodium ions from extracellular fluid through the apical membrane of cells, with water following osmotically (PubMed:24124190, PubMed:28710092, PubMed:8278374). It plays a ke

LOCALIZAÇÃO

Apical cell membraneCell projection, ciliumCytoplasmic granuleCytoplasmCytoplasmic vesicle, secretory vesicle, acrosomeCell projection, cilium, flagellum

VIAS BIOLÓGICAS (2)
Stimuli-sensing channelsSensory perception of salty taste
MECANISMO DE DOENÇA

Pseudohypoaldosteronism 1B1, autosomal recessive

A form of pseudohypoaldosteronism type 1, a rare salt wasting disease resulting from target organ unresponsiveness to mineralocorticoids. The disorder affects multiple organs, and is characterized by an often fulminant presentation in the neonatal period with dehydration, hyponatremia, hyperkalemia, metabolic acidosis, failure to thrive and weight loss.

EXPRESSÃO TECIDUAL(Ubíquo)
Glândula salivar
160.4 TPM
Rim - Medula
137.4 TPM
Esôfago - Mucosa
129.2 TPM
Tireoide
128.6 TPM
Pulmão
77.2 TPM
OUTRAS DOENÇAS (6)
pseudohypoaldosteronism, type IB1, autosomal recessivebronchiectasis with or without elevated sweat chloride 2Liddle syndrome 3Liddle syndrome
HGNC:10599UniProt:P37088
KLHL3Kelch-like protein 3Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Substrate-specific adapter of a BCR (BTB-CUL3-RBX1) E3 ubiquitin ligase complex that acts as a regulator of ion transport in the distal nephron (PubMed:14528312, PubMed:22406640, PubMed:23387299, PubMed:23453970, PubMed:23576762, PubMed:23665031, PubMed:25313067, PubMed:35093948). The BCR(KLHL3) complex acts by mediating ubiquitination and degradation of WNK1 and WNK4, two activators of Na-Cl cotransporter SLC12A3/NCC in distal convoluted tubule cells of kidney, thereby regulating NaCl reabsorpt

LOCALIZAÇÃO

Cytoplasm, cytosolCytoplasm, cytoskeleton

VIAS BIOLÓGICAS (2)
Antigen processing: Ubiquitination & Proteasome degradationNeddylation
MECANISMO DE DOENÇA

Pseudohypoaldosteronism 2D

A disorder characterized by severe hypertension, hyperkalemia, hyperchloremia, hyperchloremic metabolic acidosis, and correction of physiologic abnormalities by thiazide diuretics. PHA2D inheritance is autosomal dominant or recessive.

EXPRESSÃO TECIDUAL(Ubíquo)
Cérebro - Hemisfério cerebelar
66.8 TPM
Cerebelo
66.0 TPM
Nervo tibial
15.3 TPM
Tireoide
14.7 TPM
Testículo
12.7 TPM
OUTRAS DOENÇAS (1)
pseudohypoaldosteronism type 2D
HGNC:6354UniProt:Q9UH77
SCNN1BEpithelial sodium channel subunit betaDisease-causing germline mutation(s) inTolerante
FUNÇÃO

This is one of the three pore-forming subunits of the heterotrimeric epithelial sodium channel (ENaC), a critical regulator of sodium balance and fluid homeostasis (PubMed:30251954, PubMed:32729833, PubMed:7762608, PubMed:9792722). ENaC operates in epithelial tissues, where it mediates the electrodiffusion of sodium ions from extracellular fluid through the apical membrane of cells, with water following osmotically (PubMed:24124190). It plays a key role in maintaining sodium homeostasis through

LOCALIZAÇÃO

Apical cell membraneCytoplasmic vesicle membrane

VIAS BIOLÓGICAS (2)
Stimuli-sensing channelsSensory perception of salty taste
MECANISMO DE DOENÇA

Pseudohypoaldosteronism 1B2, autosomal recessive

A form of pseudohypoaldosteronism type 1, a rare salt wasting disease resulting from target organ unresponsiveness to mineralocorticoids. The disorder affects multiple organs, and is characterized by an often fulminant presentation in the neonatal period with dehydration, hyponatremia, hyperkalemia, metabolic acidosis, failure to thrive and weight loss.

EXPRESSÃO TECIDUAL(Ubíquo)
Esôfago - Mucosa
79.6 TPM
Vagina
59.3 TPM
Skin Not Sun Exposed Suprapubic
38.9 TPM
Skin Sun Exposed Lower leg
37.9 TPM
Pulmão
34.9 TPM
OUTRAS DOENÇAS (6)
pseudohypoaldosteronism, type IB2, autosomal recessiveLiddle syndrome 1bronchiectasis with or without elevated sweat chloride 1Liddle syndrome
HGNC:10600UniProt:P51168
SCNN1GEpithelial sodium channel subunit gammaDisease-causing germline mutation(s) inRestrito
FUNÇÃO

This is one of the three pore-forming subunits of the heterotrimeric epithelial sodium channel (ENaC), a critical regulator of sodium balance and fluid homeostasis (PubMed:30251954, PubMed:32729833, PubMed:7550319, PubMed:7762608, PubMed:9792722). ENaC operates in epithelial tissues, where it mediates the electrodiffusion of sodium ions from extracellular fluid through the apical membrane of cells, with water following osmotically (PubMed:24124190). It plays a key role in maintaining sodium home

LOCALIZAÇÃO

Apical cell membrane

VIAS BIOLÓGICAS (2)
Stimuli-sensing channelsSensory perception of salty taste
MECANISMO DE DOENÇA

Liddle syndrome 2

A form of Liddle syndrome, an autosomal dominant disorder characterized by early onset of hypertension, hypokalemic alkalosis, and suppression of plasma renin activity and aldosterone secretion.

EXPRESSÃO TECIDUAL(Tecido-específico)
Rim - Medula
47.1 TPM
Rim - Córtex
25.7 TPM
Vagina
22.7 TPM
Cérebro - Hemisfério cerebelar
14.9 TPM
Próstata
14.7 TPM
OUTRAS DOENÇAS (6)
pseudohypoaldosteronism, type IB3, autosomal recessiveLiddle syndrome 2bronchiectasis with or without elevated sweat chloride 3Liddle syndrome
HGNC:10602UniProt:P51170

Medicamentos e terapias

ENALAPRILPhase 2

Mecanismo: Angiotensin-converting enzyme inhibitor

Ver mais no OpenTargets

Variantes genéticas (ClinVar)

466 variantes patogênicas registradas no ClinVar.

🧬 CUL3: NM_003590.5(CUL3):c.1105del (p.Thr369fs) ()
🧬 CUL3: NM_003590.5(CUL3):c.32G>A (p.Arg11Gln) ()
🧬 CUL3: GRCh37/hg19 2q33.3-37.3(chr2:206965837-242783384)x3 ()
🧬 CUL3: NM_003590.5(CUL3):c.1519del (p.Val507fs) ()
🧬 CUL3: NM_003590.5(CUL3):c.2299G>C (p.Val767Leu) ()
Ver todas no ClinVar

Classificação de variantes (ClinVar)

Distribuição de 3,581 variantes classificadas pelo ClinVar.

179
1970
1432
Patogênica (5.0%)
VUS (55.0%)
Benigna (40.0%)
VARIANTES MAIS SIGNIFICATIVAS
WNK1: NM_213655.5(WNK1):c.2395-1G>A [Likely pathogenic]
WNK1: NM_213655.5(WNK1):c.2498C>T (p.Pro833Leu) [Uncertain significance]
WNK1: NM_213655.5(WNK1):c.2158_2159dup (p.Met720fs) [Uncertain significance]
WNK1: NM_018979.4(WNK1):c.4463C>T (p.Thr1488Ile) [Uncertain significance]
WNK1: NM_018979.4(WNK1):c.4939C>T (p.Pro1647Ser) [Uncertain significance]

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
2Fase 22
·Pré-clínico7
Medicamentos catalogadosEnsaios clínicos· 1 medicamento · 8 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Pseudohiperaldosteronismo

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

3 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

12 ensaios clínicos encontrados, 3 ativos.

Distribuição por fase
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
286 papers (10 anos)
#1

Do Not Dismiss Incidental Hyperkalemia in Childhood: Early Recognition of Pseudohypoaldosteronism Type II.

Cureus2026 Feb

Persistent hyperkalemia in children warrants careful evaluation, as it may indicate an underlying renal tubular disorder. We report a case of persistent hyperkalemia in a three-year-old boy in which adenovirus infection unmasked latent pseudohypoaldosteronism type II (PHAII), allowing recognition prior to the development of hypertension. The patient presented with a nine-day history of fever. Initial laboratory tests showed hyperkalemia (5.8 mmol/L), mild hyponatremia, normal renal function, and normal anion gap (AG) metabolic acidosis (pH: 7.37; bicarbonate: 19.9 mmol/L; AG: 8.1 mmol/L). The patient was diagnosed with adenovirus infection. Although the fever and inflammatory markers improved within four days, the hyperkalemia persisted (6.2 mmol/L). At three and six weeks, serum potassium remained elevated (6.0 and 6.4 mmol/L, respectively) with normal AG metabolic acidosis (HCO₃⁻ 20.0 and 17.6 mmol/L, respectively; AG 12.8 and 11.4 mmol/L, respectively). Urinary potassium indices showed inappropriately low fractional excretion of potassium (FEK) and transtubular potassium gradient (TTKG) with normal renin-aldosterone levels. Subsequently, family history-taking identified early-onset hypertension in the child's father. Treatment with hydrochlorothiazide (HCTZ) resulted in normalization of serum potassium and correction of the metabolic acidosis. Genetic testing revealed a heterozygous KLHL3 variant (c.1501C>T, p.Pro501Ser), confirming the diagnosis of PHAII. This case highlights the importance of not dismissing incidentally detected hyperkalemia in children and illustrates the value of performing a structured evaluation that includes confirming the persistence of hyperkalemia, acid-base assessment, urinary potassium analysis, and family history-taking to facilitate early diagnosis of renal tubular disorders such as PHAII.

#2

Pseudohypoaldosterism: demystification using network medicine and proposed diagnostic panels.

Hormones (Athens, Greece)2026 Jan 22

Pseudohypoaldosteronism (PHA) is a rare hereditary channelopathy characterized by renal tubular dysfunction that impairs sodium reabsorption and promotes excessive potassium retention. This imbalance often results in life-threatening electrolyte disturbances during infancy, although symptoms tend to improve with age. The disease has distinct genetic forms, most commonly linked to pathogenic variants in genes encoding epithelial sodium channel (ENaC) subunits, the mineralocorticoid receptor gene NR3C2, and the CUL3, WNK1, WNK4, or KLHL3 genes. More recently, cases involving digenic co-expression defects have been reported, suggesting a broader molecular pathogenic basis. The objective of this study was to investigate the underlying mechanisms of PHA and to assess whether additional genetic contributors may participate in disease pathogenesis. A systems medicine approach was applied, combining interaction network construction with enrichment analyses. A high confidence interactome consisting of 53 nodes was generated, with CALM3 and SCN2A identified as central hubs. Enrichment analysis highlighted biological processes and pathways related to membrane depolarization, sodium ion transport, aldosterone-regulated sodium reabsorption, and gene expression in renal tissue. Two diagnostic panels were designed, namely, PHA-X (NGS-based incorporating CNV detection and ACMG/AMP curation) and PHA-4T (disease-specific databases). Findings support the conception of PHA as a network-level disorder rather than resulting from isolated mutations, offering new perspectives for diagnosis and therapy development.

#3

Tissue-specific expression and regulation of the mineralocorticoid receptor during development.

The Journal of endocrinology2026 Jan 01

This review summarizes current knowledge on the mineralocorticoid receptor (MR), a nuclear receptor encoded by the NR3C2 gene, and its ligand aldosterone. In epithelial tissues, such as the kidney, colon, salivary glands, and skin, particularly within the sweat glands, the MR plays a key role in regulating sodium reabsorption. In non-epithelial tissues, such as the brain, adipose tissue, and heart, glucocorticoids are the main physiological MR ligands due to the absence of the 11β-hydroxysteroid dehydrogenase type 2. MR expression begins during development with tissue-specific patterns. In the kidney, MR levels peak mid-gestation, decrease at birth, and then increase postnatally. Loss of MR function, as observed in pseudohypoaldosteronism type 1 causes salt-wasting syndrome. Similar patterns are seen in the heart and brain, especially the hippocampus, where it influences stress regulation. On the contrary, MR expression is maintained at birth in the lung for neonatal fluid clearance via epithelial sodium channels. It is also present in tissues such as skin, retina, and gastrointestinal tract, indicating broad physiological roles. MR expression during fetal development correlates with adaptations to extra-uterine life, such as changes in amniotic fluid osmolality and aldosterone levels. MR gene expression and activity are tightly regulated through multiple mechanisms. These include transcriptional control via two promoters, post-transcriptional regulation involving RNA-binding proteins and microRNAs, and post-translational modifications, such as phosphorylation, sumoylation, and ubiquitination. These regulatory levels ensure appropriate MR function across different tissues and developmental stages and may have implications for conditions such as hypertension and heart failure.

#4

A Novel SCNN1B Mutation in a Neonate With Systemic Pseudohypoaldosteronism Type 1: Case Report.

Clinical case reports2026 Jan

Early recognition of PHA1B in neonates with persistent hyperkalemia and hyponatremia is important for timely intervention. Genetic testing confirms the diagnosis, guiding long-term management. This case highlights a novel SCNN1B mutation, expanding the genetic spectrum and emphasizing the need for lifelong monitoring to prevent life-threatening complications.

#5

Current understanding of ENaC regulation by P2Y2/PLC/PI(4,5)P2 pathway.

Purinergic signalling2026 Jan 07

The epithelial sodium channel (ENaC) localized in the cell membrane is crucial for sodium transport and blood pressure regulation. Discovered in frog skin, ENaC is expressed in the colon, lungs, exocrine glands, and most notably in the distal nephron of the kidneys, where it limits sodium reabsorption. Mutations in ENaC cause hereditary hypertension (Liddle's syndrome) or hypotension (pseudohypoaldosteronism type 1). ENaC activity and expression are tightly controlled by various signaling molecules and second messengers. For example, urinary ATP binding to the P2Y2 receptor inhibits ENaC. ENaC also interacts with PI(4,5)P2 and the ubiquitin ligase Nedd4-2 via specific motifs. PI(4,5)P2 is essential for ENaC stability, trafficking, and gating. This review focuses on the regulatory roles of the P2Y2 receptor and PI(4,5)P2 on ENaC regulation.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC473 artigos no totalmostrando 197

2026

Do Not Dismiss Incidental Hyperkalemia in Childhood: Early Recognition of Pseudohypoaldosteronism Type II.

Cureus
2026

Pseudohypoaldosterism: demystification using network medicine and proposed diagnostic panels.

Hormones (Athens, Greece)
2026

Tissue-specific expression and regulation of the mineralocorticoid receptor during development.

The Journal of endocrinology
2026

A Novel SCNN1B Mutation in a Neonate With Systemic Pseudohypoaldosteronism Type 1: Case Report.

Clinical case reports
2026

Current understanding of ENaC regulation by P2Y2/PLC/PI(4,5)P2 pathway.

Purinergic signalling
2026

Case Report: Compound Heterozygous SCNN1B Mutations Causing Pseudohypoaldosteronism Type 1B2 in Neonatal Twins.

Molecular genetics & genomic medicine
2025

Secondary hyperaldosteronism associated with severe infantile atopic dermatitis: a case series.

Annals of pediatric endocrinology & metabolism
2026

Diagnostic pitfalls in aldosterone defects: a 9-year follow-up of early-onset pseudohypoaldosteronism type 2.

Journal of pediatric endocrinology & metabolism : JPEM
2025

Pseudohypoaldosteronism type II: The Relevance of A Challenging Diagnosis.

European journal of case reports in internal medicine
2025

Long-Term Immune Alterations After Thymectomy in Early Childhood: A Case Series.

Cureus
2025

Repeated pseudohypoaldosteronism (PHA1) in pregnancy associated with fetal growth restriction: case report and review of the literature.

BMC pregnancy and childbirth
2026

The first report of a gross deletion in the SCNN1G gene in a case presenting with hyponatremic convulsion at fifth year of treatment.

Journal of pediatric endocrinology & metabolism : JPEM
2025

Transient pseudohypoaldosteronism type I in infants with urinary tract infections and/or uropathy: insights from a French multicenter cohort.

European journal of pediatrics
2025

The functional study of novel KLHL3 missense mutations associated with pseudohypoaldosteronism type II.

Endocrine
2026

Cardiac arrest in a previously healthy infant caused by secondary pseudohypoaldosteronism: Case report and literature review.

Medicina intensiva
2025

Case Report: Functional investigation of the γENaC G532S mutation presenting as mild PHA-1B3.

Frontiers in medicine
2025

Pseudo-Hypoaldosteronism Type 2 due to New Variants of KLHL3 Gene Diagnosed in an Adult Woman With Very High Sensitivity to Hydrochlorothiazide.

Clinical case reports
2025

Sorting nexins associated with recycling complexes regulate epithelial sodium channel trafficking.

American journal of physiology. Renal physiology
2025

A case report of Graves' disease combined with pseudohypoaldosteronism type IID in a child.

Translational pediatrics
2025

Life-Threatening Hyponatremia, Hyperkalemia, and Shock in Infancy: Not Always Congenital Adrenal Hyperplasia.

Cureus
2025

Lenticulostriate vasculopathy in newborns: whole genome sequencing data analysis.

Frontiers in pediatrics
2025

Prenatal Diagnosis of Autosomal Dominant Pseudohypoaldosteronism due to NR3C2 Gene Mutation: Immediate Postnatal Oral Saline Therapy Prevents the Clinical Manifestations Resulting from Impaired Salt Balance.

Hormone research in paediatrics
2025

A case report on pseudohypoaldosteronism with a pathogenic mutation of CA12 causes autosomal recessive isolated hyperchlorhidrosis disorder.

Journal of family medicine and primary care
2025

Clinical and Biochemical Characteristics of Pseudohypoaldosteronism Type 1 with and Without Genetic Mutations: A Literature Review.

Journal of clinical medicine
2025

A Case of Secondary Pseudohypoaldosteronism in a Neonate not Due to Urinary Tract Issues.

Journal of clinical research in pediatric endocrinology
2025

Case Report: Type II Bartter syndrome with a novel KCNJ1 variant in a premature neonate presenting with features of salt-wasting congenital adrenal crisis and pseudo-hypoaldosteronism.

Frontiers in pediatrics
2025

Revelation of Gordon Syndrome: A Case of Persistent Hyperkalemia.

Cureus
2025

[Three cases of pseudohypoaldosteronism type Ⅱ].

Zhonghua xin xue guan bing za zhi
2025

Hypertension and hyperkalemia associated with Pro701Leu mutation in the NR3C2 gene: A case report.

Medicine
2025

Autosomal recessive (type 1B) pseudohypoaldosteronism: a novel mutation and its management.

BMJ case reports
2025

Case Report: Autoimmune hepatitis in a patient with pseudohypoaldosteronism type 1-insights into a rare co-occurrence.

Frontiers in pediatrics
2025

Delayed Graft Function and Tacrolimus Overdosage: A Case Report.

Chirurgia (Bucharest, Romania : 1990)
2025

Refractory Hyperkalemia With Type 4 Renal Tubular Acidosis Associated With Tubulointerstitial Nephritis and Renal Papillary Necrosis Following Intravenous Lipid Emulsion Therapy in a Cat.

Journal of veterinary emergency and critical care (San Antonio, Tex. : 2001)
2025

Functional properties of the γ-ENaC-A635V mutation in a patient with severe hyponatremia.

Hormones (Athens, Greece)
2025

Kidney involvement during the course of febrile urinary tract infection.

Pediatric nephrology (Berlin, Germany)
2024

Neonatal pseudo-hypoaldosteronism type 1 with a novel NR3C2 gene variant.

Sudanese journal of paediatrics
2025

The evolving concepts of KS-WNK1 effect on NCC activity.

American journal of physiology. Renal physiology
2024

A Rare Cause of Neonatal Salt Wasting Syndrome: Clinical Management of a Case Diagnosed with Pseudohypoaldosteronism Due to a Novel Homozygous Variant in the SCNN1B Gene.

Journal of clinical research in pediatric endocrinology
2024

Familial Hyperkalemic Hypertension.

Comprehensive Physiology
2025

Renal pseudohypoaldosteronism type 1-an adult case series including a novel gene variant.

Endocrine
2024

Pseudohypoaldosteronism type II and sensory neuropathy associated with a heterozygous pathogenic variant in KLHL3 gene, a case report.

Heliyon
2025

Hyperkalaemic acidosis: blood pressure is the diagnostic clue.

Pediatric nephrology (Berlin, Germany)
2025

Pulmonary manifestations of Pseudohypoaldosteronism type 1b: A systematic review of the literature.

Paediatric respiratory reviews
2024

Prevalence of and factors associated with Na + /K + imbalances in a population of children hospitalized with febrile urinary tract infection.

European journal of pediatrics
2024

Persistent mild hypercalcaemia in an infant with pseudohypoaldosteronism and the diagnostic challenges faced.

Journal of nephrology
2024

Pseudohypoaldosteronism Type 1b in a Saudi Female Infant Due to Homozygous Variant Gene Mutation in SCNN1A: A Case Report.

Cureus
2024

Prevalence of Hyperkalemia and Familial Hyperkalemic Hypertension in 5100 Patients Referred to a Tertiary Hypertension Unit.

Hypertension (Dallas, Tex. : 1979)
2024

Distal convoluted tubule-specific disruption of the COP9 signalosome but not its regulatory target cullin 3 causes tubular injury.

American journal of physiology. Renal physiology
2025

Eosinophilic cystitis-an obscure case of obstructive uropathy in infancy.

Pediatric nephrology (Berlin, Germany)
2024

Transient secondary pseudo-hypoaldosteronism in infants with urinary tract infections: systematic literature review.

European journal of pediatrics
2024

Novel homozygous mutation in SCNN1A gene in an Iranian boy with PHA1B.

Journal of pediatric endocrinology & metabolism : JPEM
2024

Secondary pseudohypoaldosteronism: a 15-year experience and a literature review.

Pediatric nephrology (Berlin, Germany)
2024

An unusual case of Pseudohypoaldosteronism coexisting with cystic fibrosis.

BMJ case reports
2024

Hyponatremia in babies: a 11-year single-center study.

Frontiers in pediatrics
2024

Pseudohypoaldosteronism and acquired renal aldosterone resistance with hyperkalemic type IV renal tubular acidosis in 2 cats.

Journal of veterinary internal medicine
2024

Autosomal Dominant Pseudohypoaldosteronism Type 1 in a Newborn With Failure to Thrive.

Cureus
2024

Pseudohypoaldosteronism Type 1B and Cohen Syndrome: Novel Mutation, Unusual Combination, and Presentation.

Cureus
2024

A case of secondary pseudohypoaldosteronism that presented as poor weight gain.

Clinical case reports
2024

NR3C2 microdeletions-an underrecognized cause of pseudohypoaldosteronism type 1A: a case report and literature review.

Laboratory medicine
2024

The small molecule activator S3969 stimulates the epithelial sodium channel by interacting with a specific binding pocket in the channel's β-subunit.

The Journal of biological chemistry
2024

Adult-onset transient pseudohypoaldosteronism secondary to obstructive nephropathy: a case report.

International urology and nephrology
2024

Pseudohypoaldosteronism Type II or Gordon Syndrome: A Rare Syndrome of Hyperkalemia and Hypertension With Normal Renal Function.

Cureus
2024

Cardiac arrest in a newborn: A case of pseudohypoaldosteronism.

Clinical case reports
2023

Analysis of patients presenting with serum electrolyte imbalance in terms of the differential diagnosis of pseudohypoaldosteronism.

Northern clinics of Istanbul
2023

Case report: Early molecular confirmation and sodium polystyrene sulfonate management of systemic pseudohypoaldosteronism type I.

Frontiers in endocrinology
2023

Case report: Life threatening hyponatremia in infants with urinary tract infections: two cases of type III pseudohypoaldosteronism and review of the literature.

Frontiers in pediatrics
2024

Clinical analysis of salt-wasting in infants due to genetic aetiology.

Endokrynologia Polska
2023

When the Going Gets Tough: A Case Report and Review of Calcinosis Cutis in an Infant with Pseudo-Hypoaldosteronism.

Cureus
2024

Hereditary causes of hypertension due to increased sodium transport.

Current opinion in pediatrics
2023

A Spanish Family with Gordon Syndrome Due to a Variant in the Acidic Motif of WNK1.

Genes
2024

Dysregulation of the WNK4-SPAK/OSR1 pathway has a minor effect on baseline NKCC2 phosphorylation.

American journal of physiology. Renal physiology
2022

TRANSIENT PSEUDOHYPOALDOSTERONISM SECONDARY TO URINARY TRACT INFECTION IN A MALE INFANT WITH UNILATERAL HYDRONEPHROSIS DUE TO PRIMARY OBSTRUCTIVE MEGAURETER: A CASE REPORT.

Acta clinica Croatica
2023

Insights into the diverse mechanisms and effects of variant CUL3-induced familial hyperkalemic hypertension.

Cell communication and signaling : CCS
2023

Unanticipated domain requirements for Drosophila Wnk kinase in vivo.

PLoS genetics
2023

Gordon's syndrome in pregnancy.

Obstetric medicine
2024

Association of Familial Hyperkalemia and Hypertension with Proximal Renal Tubular Acidosis and Epileptic Seizures.

Nephron
2023

Are CUL3 variants an underreported cause of congenital heart disease?

American journal of medical genetics. Part A
2023

Role of epithelial sodium channel-related inflammation in human diseases.

Frontiers in immunology
2023

[Neonatal systemic pseudohypoaldosteronism type I].

Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics
2023

KLHL3-dependent WNK4 degradation affected by potassium through the neddylation and autophagy pathway.

BMC nephrology
2023

Brugada syndrome uncovered in patient with pseudohypoaldosteronism due to hyperkalaemia.

BMJ case reports
2023

Identification of a novel KLHL3-interacting motif in the C-terminal region of WNK4.

Biochemical and biophysical research communications
2023

Pseudohypoaldosteronism type 1b in fraternal twins of a Chinese family: report of two cases and literature review.

Archives of endocrinology and metabolism
2023

The Epithelial Sodium Channel-An Underestimated Drug Target.

International journal of molecular sciences
2023

A mild and transient form of autosomal recessive pseudohypoaldosteronism type 1 caused by a novel mutation in the SCNN1A gene.

American journal of physiology. Endocrinology and metabolism
2023

[Regulation of kidney on potassium balance and its clinical significance].

Sheng li xue bao : [Acta physiologica Sinica]
2023

Classification of pseudohypoaldosteronism type II as type IV renal tubular acidosis: results of a literature review.

Endocrine journal
2023

Early-in-Life Serum Aldosterone Levels Could Predict Surgery in Patients with Obstructive Congenital Anomalies of the Kidney and Urinary Tract: A Pilot Study.

Journal of clinical medicine
2023

Cullin 3 and Blood Pressure Regulation: Insights From Familial Hyperkalemic Hypertension.

Hypertension (Dallas, Tex. : 1979)
2023

A Five-Month-Old Boy With Hypotonia, Electrolyte Derangements, and Failure to Thrive.

Cureus
2023

Control of sodium and potassium homeostasis by renal distal convoluted tubules.

Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas
2023

Errate: Salt-Losing Syndrome in a Girl with Type I and II Pseudohypoaldosteronism.

The American journal of case reports
2023

Successful Management of Systemic Pseudohypoaldosteronism Type 1 in an Infant.

Indian pediatrics
2023

Rare forms of genetic paediatric adrenal insufficiency: Excluding congenital adrenal hyperplasia.

Reviews in endocrine & metabolic disorders
2023

Aldosterone defects in infants and young children with hyperkalemia: A single center retrospective study.

Frontiers in pediatrics
2023

A novel splice site CUL3 variant in a patient with neurodevelopmental delay.

Brain & development
2022

NCC regulation by WNK signal cascade.

Frontiers in physiology
2022

Systemic Pseudohypoaldosteronism Type 1 Due to a Novel Mutation in SCNN1B Gene: A Case Report.

EJIFCC
2022

Acid-Base Imbalance in Pseudohypoaldosteronism Type 1 in Comparison With Type IV Renal Tubular Acidosis.

Journal of the Endocrine Society
2022

Salt-Losing Syndrome in a Girl with Type I and II Pseudohypoaldosteronism.

The American journal of case reports
2022

Importance of cascade family screening and precision medicine for patients with familial hyperkalaemia: a case report.

Hong Kong medical journal = Xianggang yi xue za zhi
2022

Mild Clinical Phenotype in an 8-Year-Old Boy with Pseudohypoaldosteronism Type 2E: A Diagnostic Challenge.

Indian journal of pediatrics
2022

WNK1/HSN2 mediates neurite outgrowth and differentiation via a OSR1/GSK3β-LHX8 pathway.

Scientific reports
2022

The Post-Translational Modification Networking in WNK-Centric Hypertension Regulation and Electrolyte Homeostasis.

Biomedicines
2022

Transient pseudohypoaldosteronism in infancy mainly manifested as poor appetite and vomiting: Two case reports and review of the literature.

Frontiers in pediatrics
2022

Neonatal Pseudohypoaldosteronism Type-1 in Japan.

Journal of clinical medicine
2022

Cullin 3 mutant causing familial hyperkalemic hypertension lacks normal activity in the kidney.

American journal of physiology. Renal physiology
2022

Pseudohypoaldosteronism associated with hypertrophic cardiomyopathy, hypertension and thrombocytosis due to mutation in the ELAC2 gene: a case report.

Journal of pediatric endocrinology & metabolism : JPEM
2022

A case of severe systemic type 1 pseudohypoaldosteronism with 10 years of evolution.

Journal of pediatric endocrinology & metabolism : JPEM
2023

Mechanistic insights into the primary and secondary alterations of renal ion and water transport in the distal nephron.

Journal of internal medicine
2022

Difficulties in the diagnosis and management of eight infants with secondary pseudohypoaldosteronism.

The Turkish journal of pediatrics
2022

Challenges of Diagnosing Pseudohypoaldosteronism (PHA) in an Infant.

Case reports in endocrinology
2022

Double synonymous mutations in exon 9 of the Cullin3 gene restore exon inclusion by abolishing hnRNPs inhibition.

Human molecular genetics
2022

A case of novel mutation of Cullin 3 gene in pseudohypoaldosteronism type II.

Journal of hypertension
2022

Generation and analysis of pseudohypoaldosteronism type II knock-in mice caused by a nonsense KLHL3 mutation in the Kelch domain.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology
2022

Kelch-like protein 3 in human disease and therapy.

Molecular biology reports
2022

Cullin 3 Exon 9 Deletion in Familial Hyperkalemic Hypertension Impairs Cullin3-Ring-E3 Ligase (CRL3) Dynamic Regulation and Cycling.

International journal of molecular sciences
2022

Pseudohypoaldosteronism Type 1: The Presentation and Management of a Neonate With a Novel Mutation of the SCNN1B Gene Found in Two Hispanic Siblings.

Cureus
2022

UBR5 is a novel regulator of WNK1 stability.

American journal of physiology. Cell physiology
2022

Pseudohypoaldosteronism type 2: CUL3 mutation confirmed 15 years following initial diagnosis.

Internal medicine journal
2022

Case Report: A Novel Compound Heterozygote Mutation of the SCNN1B Gene Identified in a Chinese Familial Pseudohypoaldosteronism Disease Type I With Persistent Hyperkalemia.

Frontiers in pediatrics
2022

Claudins in kidney health and disease.

Kidney research and clinical practice
2022

Asymptomatic hyperkalemia as a form of presentation of pseudohypoaldosteronism.

Anales de pediatria
2022

Sequence and structural variations determining the recruitment of WNK kinases to the KLHL3 E3 ligase.

The Biochemical journal
2022

A Novel Homozygous KLHL3 Mutation as a Cause of Autosomal Recessive Pseudohypoaldosteronism Type II Diagnosed Late in Life.

Nephron
2022

Pseudo-hypoaldosteronism secondary to infantile urinary tract infections: role of ultrasound.

Italian journal of pediatrics
2022

Combined Kelch-like 3 and Cullin 3 Degradation is a Central Mechanism in Familial Hyperkalemic Hypertension in Mice.

Journal of the American Society of Nephrology : JASN
2022

Familial hyperkalemic hypertension: hyperkalemia not hypertension defines dominant KLHL3 disease and may permit earlier recognition and tailored therapy.

Journal of nephrology
2022

Diagnostic and management considerations in pseudohypoaldosteronism type 1b.

BMJ case reports
2021

A Neonate with Autosomal Dominant Pseudohypoaldosteronism Type 1 Due to a Novel Microdeletion of the NR3C2 Gene at 4q31.23.

Children (Basel, Switzerland)
2023

Unusual skin and eyelid changes in a neonate with pseudohypoaldosteronism.

Archives of disease in childhood. Fetal and neonatal edition
2022

Novel CUL3 Variant Causing Familial Hyperkalemic Hypertension Impairs Regulation and Function of Ubiquitin Ligase Activity.

Hypertension (Dallas, Tex. : 1979)
2021

Case Report: Newborns With Pseudohypoaldosteronism Secondary to Excessive Gastrointestinal Losses Through High Output Stoma.

Frontiers in pediatrics
2021

An infant case of pseudohypoaldosteronism type1A caused by a novel NR3C2 variant.

Human genome variation
2021

[A Case of Pseudohypoaldosteronism Type Ⅱ (PHA2) Caused by a Novel Mutation of KLHL3].

Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition
2021

Hormone resistance in children: what primary care physicians need to know.

Acta bio-medica : Atenei Parmensis
2022

Gordon syndrome caused by a CUL3 mutation in a patient with short stature in Korea: a case report.

Journal of pediatric endocrinology & metabolism : JPEM
2021

How Much Is Too Much? Exploring Pseudohyperaldosteronism in Glycyrrhizic Acid Toxicity From Chronic Licorice Root Consumption.

Cureus
2022

Monogenic forms of low-renin hypertension: clinical and molecular insights.

Pediatric nephrology (Berlin, Germany)
2022

A late diagnosis of Pseudohypoaldosteronism type I in an infant with hypoplastic left heart syndrome presenting with failure to thrive.

Cardiology in the young
2021

A Case Report of Neonatal Vomiting due to Adrenal Hemorrhage, Abscess and Pseudohypoaldosteronism.

Journal of education & teaching in emergency medicine
2021

A Unique Genotype of Pseudohypoaldosteronism Type 1b in a Highly Consanguineous Population.

Journal of the Endocrine Society
2021

Aldosterone signaling defect in young infants: single-center report and review.

BMC endocrine disorders
2021

Systemic pseudohypoaldosteronism-1 with episodic dyslipidemia in a Sudanese child.

Endocrinology, diabetes & metabolism case reports
2021

A rare case of persistent hyperkalaemia.

Annals of clinical biochemistry
2021

Tubulopathy meets Sherlock Holmes: biochemical fingerprinting of disorders of altered kidney tubular salt handling.

Pediatric nephrology (Berlin, Germany)
2021

Novel SCNN1A gene splicing-site mutation causing autosomal recessive pseudohypoaldosteronism type 1 (PHA1) in two Italian patients belonging to the same small town.

Italian journal of pediatrics
2021

Regulatory control of the Na-Cl co-transporter NCC and its therapeutic potential for hypertension.

Acta pharmaceutica Sinica. B
2022

Genotype-phenotype correlation in Gordon's syndrome: report of two cases carrying novel heterozygous mutations.

Journal of nephrology
2021

Case Report: Severe Hyponatremia in Infants With Urinary Tract Infection.

Frontiers in pediatrics
2021

Transient Pseudohypoaldosteronism Secondary to Group B Streptococcus Pyelonephritis.

Cureus
2021

A case report of pseudohypoaldosteronism type II with a homozygous KLHL3 variant accompanied by hyperthyroidism.

BMC endocrine disorders
2021

A rare cause of salt-wasting in early infancy: Transient pseudohypoaldosteronism.

Turkish archives of pediatrics
2021

Activation of autosomal recessive Pseudohypoaldosteronism1 ENaC with aldosterone.

European journal of pharmacology
2022

A Novel SCNN1A Variation in a Patient with Autosomal-recessive Pseudohypoaldosteronism Type 1.

Journal of clinical research in pediatric endocrinology
2021

Secondary Pseudohypoaldosteronism Associated With Mild Hydronephrosis in a Newborn.

Cureus
2021

Clinical characteristics and treatment requirements of children with autosomal recessive pseudohypoaldosteronism.

European journal of endocrinology
2021

Role of KLHL3 and dietary K+ in regulating KS-WNK1 expression.

American journal of physiology. Renal physiology
2021

WNK4 kinase: from structure to physiology.

American journal of physiology. Renal physiology
2021

Decreased KLHL3 expression is involved in the activation of WNK-OSR1/SPAK-NCC cascade in type 1 diabetic mice.

Pflugers Archiv : European journal of physiology
2020

A Case of Salt-Wasting 21-Hydroxylase Deficiency With Resistance to Aldosterone due to Urinary Tract Infection.

Cureus
2021

The incidence of transient infantile pseudohypoaldosteronism in Ireland: A prospective study.

Acta paediatrica (Oslo, Norway : 1992)
2020

Metabolic Acidosis, Hyperkalemia, and Renal Unresponsiveness to Aldosterone Syndrome: Response to Treatment with Low-Potassium Diet.

Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia
2021

Three cases of pseudohypoaldosteronism following ileostomy in preterm infants.

Pediatrics and neonatology
2020

Renin-aldosterone system evaluation over four decades in an extended family with autosomal dominant pseudohypoaldosteronism due to a deletion in the NR3C2 gene.

The Journal of steroid biochemistry and molecular biology
2022

A comparative study of structural and conformational properties of WNK kinase isoforms bound to an inhibitor: insights from molecular dynamic simulations.

Journal of biomolecular structure & dynamics
2021

Clinical Management in Systemic Type Pseudohypoaldosteronism Due to SCNN1B Variant and Literature Review.

Journal of clinical research in pediatric endocrinology
2020

Hyperkalemia in pseudohypoaldosteronism type 2 can be from mutated WNK4, but more often from impaired ubiquitination of normal WNK4.

Kidney international
2020

Aldosterone deficiency with a hormone profile mimicking pseudohypoaldosteronism.

Journal of pediatric endocrinology & metabolism : JPEM
2020

Mutation affecting the conserved acidic WNK1 motif causes inherited hyperkalemic hyperchloremic acidosis.

The Journal of clinical investigation
2021

WNK-SPAK/OSR1-NCC kinase signaling pathway as a novel target for the treatment of salt-sensitive hypertension.

Acta pharmacologica Sinica
2020

An infantile case of pseudohypoaldosteronism type 1 (PHA1) caused by a novel mutation of NR3C2.

Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology
2020

WNK1-OSR1/SPAK KINASE CASCADE IS IMPORTANT FOR ANGIOGENESIS.

Transactions of the American Clinical and Climatological Association
2020

Familial cases of pseudohypoaldosteronism type II harboring a novel mutation in the Cullin 3 gene.

Nephrology (Carlton, Vic.)
2020

Rare case of pseudohypoaldosteronism in a neonate secondary to congenital hydrometrocolpos.

BMJ case reports
2020

[Severity of familial hyperkalemic hypertension caused by CUL-3 mutations: a story about kidneys and blood vessels].

Medecine sciences : M/S
2020

Pseudohypoaldosteronism Type 1 Newborn Patient with a Novel Mutation in SCNN1B.

Journal of pediatric intensive care
2020

The WNK signaling pathway and salt-sensitive hypertension.

Hypertension research : official journal of the Japanese Society of Hypertension
2020

Hereditary causes of primary aldosteronism and other disorders of apparent excess mineralocorticoid activity.

Gland surgery
2020

Recent insights into sodium and potassium handling by the aldosterone-sensitive distal nephron: implications on pathophysiology and drug discovery.

Journal of nephrology
2020

Interstitial 4q Deletion Syndrome Including NR3C2 Causing Pseudohypoaldosteronism.

Molecular syndromology
2020

Failure to Thrive, Hyponatremia, Hyperkalemia - Differential Diagnostic Reflections of a Rare Genetic Disease.

Klinische Padiatrie
2020

Dietary potassium restriction attenuates urinary sodium wasting in the generalized form of pseudohypoaldosteronism type 1.

CEN case reports
2019

One-month-old girl presenting with pseudohypoaldosteronism leading to the diagnosis of CDK13-related disorder: a case report and review of the literature.

Journal of medical case reports
2020

Prevalence, diagnosis, and management of secondary pseudohypoaldosteronism.

Pediatric nephrology (Berlin, Germany)
2020

Familial Hyperkalemic Hypertension Genotype With a Negative Phenotype: A CUL3 Mosaicism.

American journal of hypertension
2019

Life threatening hyperkalemia treated with prolonged continuous insulin infusion.

International journal of pediatrics & adolescent medicine
2020

Rare cause of severe hypertension in an adolescent boy presenting with short stature: Answers.

Pediatric nephrology (Berlin, Germany)
2019

A novel SCNN1G mutation in a PHA I infant patient correlates with nephropathy.

Biochemical and biophysical research communications
2019

The Case | Severe hypertension and hyperkalemia in a kidney transplant recipient.

Kidney international
2019

Cullin-Ring ubiquitin ligases in kidney health and disease.

Current opinion in nephrology and hypertension
2019

Phenotypic diversity and correlation with the genotypes of pseudohypoaldosteronism type 1.

Journal of pediatric endocrinology & metabolism : JPEM
2019

Hyponatremia in children under 100 days old: incidence and etiologies.

European journal of pediatrics
2019

An infant with hyponatremia, hyperkalemia, and metabolic acidosis associated with urinary tract infection: Answers.

Pediatric nephrology (Berlin, Germany)
2019

A familial case of pseudohypoaldosteronism type II (PHA2) with a novel mutation (D564N) in the acidic motif in WNK4.

Molecular genetics & genomic medicine
2019

Systemic Pseudohypoaldosteronism Type 1 due to 3 Novel Mutations in SCNN1Aand SCNN1BGenes.

Hormone research in paediatrics
2020

Investigating specificity of the anti-hypertensive inhibitor WNK463 against With-No-Lysine kinase family isoforms via multiscale simulations.

Journal of biomolecular structure & dynamics
Ver todos os 473 no EuropePMC

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Pseudohiperaldosteronismo.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Pseudohiperaldosteronismo

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Do Not Dismiss Incidental Hyperkalemia in Childhood: Early Recognition of Pseudohypoaldosteronism Type II.
    Cureus· 2026· PMID 41841078mais citado
  2. Pseudohypoaldosterism: demystification using network medicine and proposed diagnostic panels.
    Hormones (Athens, Greece)· 2026· PMID 41569463mais citado
  3. Tissue-specific expression and regulation of the mineralocorticoid receptor during development.
    The Journal of endocrinology· 2026· PMID 41543024mais citado
  4. A Novel SCNN1B Mutation in a Neonate With Systemic Pseudohypoaldosteronism Type 1: Case Report.
    Clinical case reports· 2026· PMID 41522852mais citado
  5. Current understanding of ENaC regulation by P2Y2/PLC/PI(4,5)P2 pathway.
    Purinergic signalling· 2026· PMID 41498836mais citado
  6. Clinical and molecular characteristics of a series of Chinese children with pseudohypoaldosteronism: a case series.
    Transl Pediatr· 2026· PMID 41982973recente
  7. Congenital aldosterone deficiency and its resistance.
    Endocr J· 2026· PMID 41905953recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:444916(Orphanet)
  2. MONDO:0018638(MONDO)
  3. GARD:21861(GARD (NIH))
  4. Variantes catalogadas(ClinVar)
  5. Busca completa no PubMed(PubMed)
  6. Q200745(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Pseudohiperaldosteronismo
Compêndio · Raras BR

Pseudohiperaldosteronismo

ORPHA:444916 · MONDO:0018638
CID-10
N25.8 · Outros transtornos resultantes de função renal tubular alterada
Ensaios
3 ativos
Medicamentos
1 registrados
MedGen
UMLS
C0033805
EuropePMC
Wikidata
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades